- Zacks Small Cap Research•2 days ago
MediciNova (MNOV) is developing MN-166 (ibudilast) for the treatment of primary and secondary progressive multiple sclerosis (PPMS and SPMS), amyotrophic lateral sclerosis (ALS), methamphetamine (MA) addiction, opioid dependence, and alcohol dependence. The drug is currently being tested in four separate clinical trials in the aforementioned indications with two trials recently completed in alcohol dependence and opioid dependence. MN-166 is an anti-inflammatory drug that has been used for over 20 years in Japan to treat asthma (Rolan et al., 2009) and post-stroke dizziness.
- Capital Cube•2 months ago
Click here to see latest analysisMediciNova, Inc. reports financial results for the quarter ended March 31, 2016.AnalysisSummary numbers: Revenues of USD 0 million, Net Earnings of USD -3.38 million.The company did not record any revenues for the last twelve months making the comparison of net margin versus asset turnover meaningless.MNOV-US‘s earnings and EBITDA are both […] (Read more...) The post MediciNova, Inc. :MNOV-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 appeared first on CapitalCube.
After hours: 6.20-0.00 (-0.02%) as of 4:46 PM EDT
|Bid||5.19 x 100|
|52wk Range||2.62 - 10.16|
|Day's Range||5.97 - 6.36|
|Avg Vol (3m)||169,246|
As of 4:00 PM EDT. Market closed.